“ϊ–{ˆγ‰Θ‘εŠwˆγŠw‰οŽGŽ Online Journal ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚π”ς‚Ξ‚·
‘–ΪŽŸ > †–ΪŽŸ > Abstract ƒz[ƒ€‚Φ–ί‚ι
Abstract

‘ζ15Šͺ 2019”N2ŒŽ@‘ζ1†

‘S•ΆPDF (577K)

‘Œ΄’˜

ƒGƒsƒiƒXƒ`ƒ“‰–Ž_‰–“_Šα‰t0.05“‚Μ“_Šα‰ρ”ŒyŒΈ‚Μ—LŒψ«
¬—с@–ΞŽχ
¬—ΡŠα‰Θˆγ‰@

Efficacy of Reduced-dose Epinastine Hydrochloride Ophthalmic Solution 0.05%
Shigeki Kobayashi
Kobayashi Eye Clinic

Purpose: To evaluate the efficacy of using 1 drop twice daily of epinastine hydrochloride ophthalmic solution 0.05% (epinastine eye drops) instead of the recommended 1 drop 4 times daily in patients with allergic conjunctivitis.
Subjects and Methods: Thirteen patients with subjective symptoms of allergic conjunctivitis who had not used epinastine eye drops and who visited our clinic in March and April 2017 were included in this study; they were instructed to use 1 drop twice daily. The subjective symptoms and objective findings before and after therapy were quantified at follow-up and statistically analyzed using the Wilcoxon signed-rank test. If improvement was insufficient with twice-daily administration, the dosing regimen was changed to 4 times daily.
Results: Excluding 1 subject who did not appear for the follow-up after initiation of therapy, the dose remained at twice daily in all 12 subjects. Itching was the only subjective symptom in all subjects. A comparison of subjective symptoms before and after therapy showed significant improvement in subjective symptoms (p<0.002) and objective findings (p<0.005) after therapy.
Conclusions: Reduced-dose therapy resulted in medication compliance. Since most children are not administered eye drops by school staff, twice-daily instillation enables parents to provide treatment at home.

“ϊˆγ‘εˆγ‰οŽ 2019; 15(1), 8-11

Key words
epinastine hydrochloride ophthalmic solution 0.05%, allergic conjunctivitis, reduced-dose therapy, dimple bottle

Correspondence to
Shigeki Kobayashi, Kobayashi Eye Clinic, 1-28 Showa-machi, Aoba-ku, Sendai Miyagi 981-0913, Japan
E-mailFkame42@herb.ocn.ne.jp

Žσ•tF2018”N8ŒŽ3“ϊ@Žσ—F2018”N9ŒŽ27“ϊ

ƒƒCƒ“ƒiƒrƒQ[ƒVƒ‡ƒ“‚Φ–ί‚ι ‚±‚Μƒy[ƒW‚Μƒgƒbƒv‚Φ–ί‚ι